TRAVELZOO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TRAVELZOO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2018 | $27.06M | Mar 11, 2019 |
| FY2017 | Sep 30, 2018 | $25.30M | Mar 11, 2019 |
| FY2017 | Jun 30, 2018 | $28.08M | Mar 11, 2019 |
| FY2017 | Mar 31, 2018 | $30.88M | Mar 11, 2019 |
| FY2017 | Dec 31, 2017 | $27.00M | Mar 11, 2019 |
| FY2017 | Sep 30, 2017 | $24.69M | Mar 11, 2019 |
| FY2017 | Jun 30, 2017 | $26.41M | Mar 11, 2019 |
| FY2017 | Mar 31, 2017 | $28.43M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $114.26M | Mar 11, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.72M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $83.90M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $84.48M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $70.60M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $62.71M | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | $12.48M | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | $13.79M | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $7.00M | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $20.33M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $25.33M | Mar 31, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.64M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $73.43M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $73.54M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $60.60M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $51.32M | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | $9.69M | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | $10.86M | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $4.86M | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $17.62M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $22.28M | Mar 31, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.70M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $13.56M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $12.37M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $6.63M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $911.0K | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | $727.0K | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | ($1.35M) | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | ($6.19M) | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | ($6.61M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | ($599.0K) | Mar 20, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.90M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $18.50M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $15.57M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $7.56M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($1.31M) | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | ($897.0K) | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | ($1.20M) | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | ($6.63M) | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | ($5.34M) | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $2.93M | Mar 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.41M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $2.11M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $2.06M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.59M | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | $495.0K | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | $592.0K | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | $566.0K | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | $1.43M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $1.85M | Mar 31, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.66M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $21.10M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $10.68M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | ($23.12M) | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($8.08M) | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $47.02M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $11.24M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.32M | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | $2.08M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $8.72M | Mar 11, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.0K | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $177.0K | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $255.0K | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $462.0K | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $29.0K | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $253.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $474.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $752.0K | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | $738.0K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $909.0K | Mar 11, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.19M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $54.72M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $55.38M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $67.27M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $99.73M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $102.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $54.54M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $43.42M | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | $45.67M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $53.53M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.61M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $50.37M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $46.50M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $58.42M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $99.36M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $95.90M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $43.68M | Mar 31, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.52M) | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | ($462.0K) | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.19M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $4.26M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | ($4.23M) | Aug 14, 2023 |
| FY2022 | Dec 31, 2020 | $1.89M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $10.86M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $14.06M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $13.08M | Mar 20, 2020 |
| FY2017 | Dec 31, 2016 | $18.06M | Mar 11, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.94M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $10.94M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $10.94M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $10.94M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $10.94M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $10.94M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 31, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.24M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $14.28M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $19.51M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $7.14M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $508.0K | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | ($403.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.20M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $18.15M | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | $16.55M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $21.72M | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.01M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | $17.06M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | $15.71M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | $18.69M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | $43.82M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | $63.06M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.74M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $18.02M | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | $22.55M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $26.84M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Aug 14, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.93M | Mar 11, 2026 |
| FY2025 | Dec 31, 2024 | 11.84M | Mar 11, 2026 |
| FY2024 | Dec 31, 2023 | 13.58M | Mar 19, 2025 |
| FY2023 | Dec 31, 2022 | 15.70M | Mar 22, 2024 |
| FY2022 | Dec 31, 2021 | 12.06M | Aug 14, 2023 |
| FY2021 | Dec 31, 2020 | 11.37M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 11.48M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 11.96M | Mar 20, 2020 |
| FY2017 | Dec 31, 2017 | 12.46M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 13.46M | Mar 16, 2018 |